MedDataX Logo

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT ID: NCT03802630

Last Updated: 2023-01-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-02

Study Completion Date

2021-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313

Central Retinal Vein Occlusion
TERMINATED PHASE3

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634

Diabetic Macular Edema
COMPLETED PHASE3

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

NCT03710564

Age-Related Macular Degeneration
TERMINATED PHASE3

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474

Neovascular Age-related Macular Degeneration
COMPLETED PHASE3

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887

Neovascular Age-Related Macular Degeneration (NVAMD) Branch Retinal Vein Occlusion (BRVO)
RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was comprised of a Screening period (Day -28 to Day -1), Double-masked treatment period (Day 1 to Week 72) and Post-treatment follow-up period (Week 72 to Week 76). Treatment visits were scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects entered a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability was performed at each monthly visit and subjects received either an active or a sham injection. Treatment with active was interrupted when disease stability was reached.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Branch Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
A masked evaluating investigator was responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator performed the injections and assessed patient safety following the injections.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brolucizumab 6 mg

1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)

Group Type EXPERIMENTAL

Brolucizumab 6 mg

Intervention Type DRUG

Solution for injection (intravitreal use)

Sham injection

Intervention Type OTHER

Empty sterile syringe without a needle administered as a sham injection for masking purposes.

From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Aflibercept 2 mg

1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individualized flexible treatment (IFT)

Group Type ACTIVE_COMPARATOR

Aflibercept 2 mg

Intervention Type DRUG

Solution for injection (Intravitreal use)

Sham injection

Intervention Type OTHER

Empty sterile syringe without a needle administered as a sham injection for masking purposes.

From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brolucizumab 6 mg

Solution for injection (intravitreal use)

Intervention Type DRUG

Aflibercept 2 mg

Solution for injection (Intravitreal use)

Intervention Type DRUG

Sham injection

Empty sterile syringe without a needle administered as a sham injection for masking purposes.

From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RTH258 ESBA1008 EYLEA®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent must be obtained prior to participation in the study.
* Patients with visual impairment due to ME secondary to BRVO diagnosed \< 6 months prior to screening.
* BCVA score between 78 and 23 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/320) at both screening and baseline visits.

Exclusion Criteria

* Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g. structural damage of the fovea, vitreous hemorrhage, retinal vascular occlusion other than BRVO, retinal detachment, macular hole, or choroidal neovascularization of any cause, diabetic retinopathy (except mild non-proliferative) and diabetic macular edema). Hemiretinal vein occlusion should be excluded.
* Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at screening or baseline
* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 mmHg on medication, or according to investigator's judgment, at screening or baseline
* Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA \< 20/200 at screening (except when due to conditions whose surgery may improve VA, e.g. cataract)
* Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to baseline
* Previous use of intraocular or periocular steroids in study eye at any time prior to baseline
* Macular laser photocoagulation (focal/grid) in the study eye at any time prior to baseline and peripheral laser photocoagulation in the study eye within 3 months prior to the baseline
* Intraocular surgery in the study eye during the 3-month period prior to baseline
* Vitreoretinal surgery in the study eye at any time prior to baseline
* Aphakia with the absence of posterior capsule in the study eye
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Phoenix, Arizona, United States

Site Status

Novartis Investigative Site

Mountain View, California, United States

Site Status

Novartis Investigative Site

Santa Barbara, California, United States

Site Status

Novartis Investigative Site

Colorado Springs, Colorado, United States

Site Status

Novartis Investigative Site

Pensacola, Florida, United States

Site Status

Novartis Investigative Site

St. Petersburg, Florida, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

New Albany, Indiana, United States

Site Status

Novartis Investigative Site

Leawood, Kansas, United States

Site Status

Novartis Investigative Site

Lenexa, Kansas, United States

Site Status

Novartis Investigative Site

Stoneham, Massachusetts, United States

Site Status

Novartis Investigative Site

Reno, Nevada, United States

Site Status

Novartis Investigative Site

Bloomfield, New Jersey, United States

Site Status

Novartis Investigative Site

Asheville, North Carolina, United States

Site Status

Novartis Investigative Site

Charlotte, North Carolina, United States

Site Status

Novartis Investigative Site

Cleveland, Ohio, United States

Site Status

Novartis Investigative Site

Monroeville, Pennsylvania, United States

Site Status

Novartis Investigative Site

Abilene, Texas, United States

Site Status

Novartis Investigative Site

Arlington, Texas, United States

Site Status

Novartis Investigative Site

Austin, Texas, United States

Site Status

Novartis Investigative Site

Austin, Texas, United States

Site Status

Novartis Investigative Site

Bellaire, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

Houston, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

Madison, Wisconsin, United States

Site Status

Novartis Investigative Site

Graz, , Austria

Site Status

Novartis Investigative Site

Calgary, Alberta, Canada

Site Status

Novartis Investigative Site

London, Ontario, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Québec, , Canada

Site Status

Novartis Investigative Site

Guangzhou, Guangdong, China

Site Status

Novartis Investigative Site

Wuhan, Hubei, China

Site Status

Novartis Investigative Site

Wuxi, Jiangsu, China

Site Status

Novartis Investigative Site

Chengdu, Sichuan, China

Site Status

Novartis Investigative Site

Tianjin, Tianjin Municipality, China

Site Status

Novartis Investigative Site

Tianjin, Tianjin Municipality, China

Site Status

Novartis Investigative Site

Wenzhou, Zhejiang, China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Chongqing, , China

Site Status

Novartis Investigative Site

Shanghai, , China

Site Status

Novartis Investigative Site

Pardubice, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Prague, , Czechia

Site Status

Novartis Investigative Site

Copenhagen, , Denmark

Site Status

Novartis Investigative Site

Strasbourg, Bas Rhin, France

Site Status

Novartis Investigative Site

Saint-Cyr-sur-Loire, Indre Et Loire, France

Site Status

Novartis Investigative Site

Bordeaux, , France

Site Status

Novartis Investigative Site

Créteil, , France

Site Status

Novartis Investigative Site

Dijon, , France

Site Status

Novartis Investigative Site

Marseille, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Paris, , France

Site Status

Novartis Investigative Site

Regensburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Düsseldorf, , Germany

Site Status

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Ludwigshafen, , Germany

Site Status

Novartis Investigative Site

Mainz, , Germany

Site Status

Novartis Investigative Site

Münster, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Hong Kong, , Hong Kong

Site Status

Novartis Investigative Site

Jerusalem, , Israel

Site Status

Novartis Investigative Site

Petah Tikva, , Israel

Site Status

Novartis Investigative Site

Ẕerifin, , Israel

Site Status

Novartis Investigative Site

Catania, CT, Italy

Site Status

Novartis Investigative Site

Pisa, PI, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Roma, RM, Italy

Site Status

Novartis Investigative Site

Udine, UD, Italy

Site Status

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Site Status

Novartis Investigative Site

Amagasaki, Hyōgo, Japan

Site Status

Novartis Investigative Site

Ishioka, Ibaraki, Japan

Site Status

Novartis Investigative Site

Chiyoda-ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Taito-ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Osaka, , Japan

Site Status

Novartis Investigative Site

Arecibo, , Puerto Rico

Site Status

Novartis Investigative Site

Cheboksary, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Saratov, , Russia

Site Status

Novartis Investigative Site

Sterlitamak, , Russia

Site Status

Novartis Investigative Site

Bratislava, , Slovakia

Site Status

Novartis Investigative Site

Nitra, , Slovakia

Site Status

Novartis Investigative Site

Zvolen, , Slovakia

Site Status

Novartis Investigative Site

Seville, Andalusia, Spain

Site Status

Novartis Investigative Site

Sant Cugat del Vallès, Catalonia, Spain

Site Status

Novartis Investigative Site

Santiago de Compostela, Galicia, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Madrid, , Spain

Site Status

Novartis Investigative Site

Lausanne, Canton of Vaud, Switzerland

Site Status

Novartis Investigative Site

Binningen, , Switzerland

Site Status

Novartis Investigative Site

Changhua, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Westcliff-on-Sea, Essex, United Kingdom

Site Status

Novartis Investigative Site

Bradford, West Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Birmingham, , United Kingdom

Site Status

Novartis Investigative Site

Liverpool, , United Kingdom

Site Status

Novartis Investigative Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Canada China Czechia Denmark France Germany Hong Kong Israel Italy Japan Puerto Rico Russia Slovakia Spain Switzerland Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17957

Results for CRTH258C2301 from the Novartis Clinical Trials Website

https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1191

A Plain Language Trial Summary is available on novctrd.com

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-001842-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CRTH258C2301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
NCT01521559 COMPLETED PHASE3
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
NCT02307682 COMPLETED PHASE3
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
NCT04047472 COMPLETED PHASE3
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
NCT04239027 COMPLETED PHASE3
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935 COMPLETED PHASE4
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
NCT04632056 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
NCT04740905 COMPLETED PHASE3
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
NCT04597632 COMPLETED PHASE3
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
NCT03930641 COMPLETED PHASE3
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
NCT05850520 COMPLETED PHASE3
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
NCT05266495 TERMINATED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
NCT04740931 COMPLETED PHASE3
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
NCT04264819 COMPLETED PHASE3
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
NCT04005352 COMPLETED PHASE3
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
NCT05473715 TERMINATED PHASE4
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
NCT06178770 COMPLETED
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT03714308 COMPLETED
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
NCT04697953 WITHDRAWN PHASE3
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
NCT06398080 WITHDRAWN
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
NCT02718326 COMPLETED PHASE3
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
NCT04126317 COMPLETED PHASE2
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
NCT05037396 COMPLETED
Evaluation of IBI302 Injection in nAMD or DME
NCT05961007 SUSPENDED PHASE1/PHASE2
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
NCT04049266 TERMINATED PHASE2/PHASE3
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891 COMPLETED PHASE4